Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma

Radiation Oncology

Wayne D Newhauser¹  Kenneth L Homann³  Anthony M D’Amelio⁴  Carol J Etzel⁴  Anita Mahajan⁵  Wendi Koontz-Raisig²  Annelise Giebeler³  Rebecca M Howell⁶ 

[1] Present Address: Louisiana State University, Department of Physics and Astronomy, Baton Rouge, LA, USA;Department of Radiation Oncology, The Emory Clinic, Atlanta, GA, USA;Graduate School of Biomedical Sciences, The University of Texas at Houston, Houston, TX, USA;Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Department of Radiation Physics, Unit 094, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

关键词: Medulloblastoma;    CSI;    Craniospinal irradiation;    Photon;    Proton;   

Others  :  1228580
DOI  :  10.1186/1748-717X-7-116

 received in 2012-03-26, accepted in 2012-07-24,  发布年份 2012

【 摘 要 】

Background

For many decades, the standard of care radiotherapy regimen for medulloblastoma has been photon (megavoltage x-rays) craniospinal irradiation (CSI). The late effects associated with CSI are well-documented in the literature and are in-part attributed to unwanted dose to healthy tissue. Recently, there is growing interest in using proton therapy for CSI in pediatric and adolescent patients to reduce this undesirable dose. Previous comparisons of dose to target and non-target organs from conventional photon CSI and passively scattered proton CSI have been limited to small populations (n ≤ 3) and have not considered the use of age-dependent target volumes in proton CSI.

Methods

Standard of care treatment plans were developed for both photon and proton CSI for 18 patients. This cohort included both male and female medulloblastoma patients whose ages, heights, and weights spanned a clinically relevant and representative spectrum (age 2–16, BMI 16.4–37.9 kg/m2). Differences in plans were evaluated using Wilcoxon signed rank tests for various dosimetric parameters for the target volumes and normal tissue.

Results

Proton CSI improved normal tissue sparing while also providing more homogeneous target coverage than photon CSI for patients across a wide age and BMI spectrum. Of the 24 parameters (V₅, V₁₀, V₁₅, and V₂₀ in the esophagus, heart, liver, thyroid, kidneys, and lungs) Wilcoxon signed rank test results indicated 20 were significantly higher for photon CSI compared to proton CSI (p ≤ 0.05) . Specifically, V₁₅ and V₂₀ in all six organs and V₅, V₁₀ in the esophagus, heart, liver, and thyroid were significantly higher with photon CSI.

Conclusions

Our patient cohort is the largest, to date, in which CSI with proton and photon therapies have been compared. This work adds to the body of literature that proton CSI reduces dose to normal tissue compared to photon CSI for pediatric patients who are at substantial risk for developing radiogenic late effects. Although the present study focused on medulloblastoma, our findings are generally applicable to other tumors that are treated with CSI.

【 授权许可】

   
2012 Howell et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Dhall G: Medulloblastoma. J Child Neurol 2009, 24(11):1418-1430.
• [2]Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ: Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (st jude medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol 2006, 7(10):813-820.
• [3]Gilbertson RJ: Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004, 5(4):209-218.
• [4]Deutsch M, Reigel DH: The value of myelography in the management of childhood medulloblastoma. Cancer 1980, 45(8):2194-2197.
• [5]Allen JC, Epstein F: Medulloblastoma and other primary malignant neuroectodermal tumors of the cns - the effect of patients age and extent of disease on prognosis. J Neurosurg 1982, 57(4):446-451.
• [6]Fouladi M, Gajjar A, Boyett JM, Walter AW, Thompson SJ, Merchant TE, Jenkins JJ, Langston LW, Liu AY, Kun LE, Heideman RL: Comparison of csf cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 1999, 17(10):3234-3237.
• [7]Freeman CR, Taylor RE, Kortmann RD, Carrie C: Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Medical and Pediatric Oncology 2002, 39(2):99-108.
• [8]Packer RJ, Gajjar A, Vezina G, Rorke-Adams L, Burger PC, Robertson PL, Bayer L, LaFond D, Donahue BR, Marymont MH, Muraszko K, Langston J, Sposto R: Phase iii study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006, 24(25):4202-4208.
• [9]Packer RJ, Vezina G: Management of and prognosis with medulloblastoma therapy at a crossroads. Arch Neurol 2008, 65(11):1419-1424.
• [10]Jarlskog CZ, Lee C, Bolch WE, Xu XG, Paganetti H: Assessment of organ-specific neutron equivalent doses in proton therapy using computational whole-body age-dependent voxel phantoms. Phys Med Biol 2008, 53(3):693-717.
• [11]Jarlskog CZ, Paganetti H: Risk of developing second cancer from neutron dose in proton therapy as function of field characteristics, organ, and patient age. Int J Radiat Oncol Biol Phys 2008, 72(1):228-235.
• [12]NRC: Health risks from exposure to low levels of ionizing radation: Beir vii - phase 2. Washington, D.C: Nation Research Council of the National Academies; 2006.
• [13]Taddei PJ, Mirkovic D, Fontenot JD, Giebeler A, Zheng YS, Kornguth D, Mohan R, Newhauser WD: Stray radiation dose and second cancer risk for a pediatric patient receiving craniospinal irradiation with proton beams. Phys Med Biol 2009, 54(8):2259-2275.
• [14]Silber JH, Littman PS, Meadows AT: Stature loss following skeletal irradiation for childhood-cancer. J Clin Oncol 1990, 8(2):304-312.
• [15]Chin D, Sklar C, Donahue B, Uli N, Geneiser N, Allen J, Nirenberg A, David R, Kohn B, Oberfield SE: Thyroid dysfunction as a late effect in survivors of pediatric medulloblastoma primitive neuroectodermal tumors - a comparison of hyperfractionated versus conventional radiotherapy. Cancer 1997, 80(4):798-804.
• [16]Constine LS, Woolf PD, Cann D, Mick G, Mccormick K, Raubertas RF, Rubin P: Hypothalamic pituitary dysfunction after radiation for brain-tumors. N Engl J Med 1993, 328(2):87-94.
• [17]Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, Study CCS: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355(15):1572-1582.
• [18]Grau C, Overgaard J: Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int J Radiat Oncol Biol Phys 1996, 36(2):515-517.
• [19]Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE: Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a pediatric oncology group study. J Clin Oncol 1998, 16(5):1723-1728.
• [20]Bowers DC, Liu Y, Leisenring W, McNeil E, Stovall M, Gurney JG, Robison LL, Packer RJ, Oeffinger KC: Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the childhood cancer survivor study. J Clin Oncol 2006, 24(33):5277-5282.
• [21]Jakacki RI, Goldwein JW, Larsen RL, Barber G, Silber JH: Cardiac dysfunction following spinal irradiation during childhood. J Clin Oncol 1993, 11(6):1033-1038.
• [22]Mertens AC: Cause of mortality in 5-year survivors of childhood cancer. Pediatr Blood Cancer 2007, 48(7):723-726.
• [23]Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, Robison LL, Yasui Y: Cause-specific late mortality among 5-year survivors of childhood cancer: the childhood cancer survivor study. J Natl Cancer Inst 2008, 100(19):1368-1379.
• [24]Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, Skinner R, Stevens MC, Hawkins MM, Survivor BCC: Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010, 304(2):172-179.
• [25]Inskip PD, Curtis RE: New malignancies following childhood cancer in the united states, 1973–2002. Int J Cancer 2007, 121(10):2233-2240.
• [26]Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, Whitton JA, Diller L, Kenney L, Donaldson SS, Meadows AT, Neglia JP: Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009, 27(24):3901-3907.
• [27]Meadows AT, Friedman DL, Neglia JP, Mertens AC, Donaldson SS, Stovall M, Hammond S, Yasui Y, Inskip PD: Second neoplasms in survivors of childhood cancer: Findings from the childhood cancer survivor study cohort. J Clin Oncol 2009, 27(14):2356-2362.
• [28]Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL: Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst 2001, 93(8):618-629.
• [29]Bentel G: Radiation therapy planning: Including problems and solutions. New York: McGraw-Hill, Health Professions Division; 1996.
• [30]Lee CT, Bilton SD, Famiglietti RM, Riley BA, Mahajan A, Chang EL, Maor MH, Woo SY, Cox JD, Smith AR: Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: How do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 2005, 63(2):362-372.
• [31]Miralbell R, Lomax A, Bortfeld T, Rouzaud M, Carrie C: Potential role of proton therapy in the treatment of pediatric medulloblastoma primitive neuroectodermal tumors: Reduction of the supratentorial target volume. Int J Radiat Oncol Biol Phys 1997, 38(3):477-484.
• [32]Slater JD, Yuh GE, Loredo LN, Yonemoto LT, Bush DA, Shahnazi K, Preston W, Slater JM: Reducing toxicity from craniospinal irradiation: Using proton beams to treat medulloblastoma in young children. Cancer J 2004, 10(6):386-390.
• [33]St Clair WH, Adams JA, Bues M, Fullerton BC, La Shell S, Kooy HM, Loeffler JS, Tarbell NJ: Advantage of protons compared to conventional x-ray or IMRT in the treatment of a pediatric patient with medulloblastoma. Int J Radiat Oncol Biol Phys 2004, 58(3):727-734.
• [34]Newhauser W, Fontenot J, Zheng YS, Polf J, Titt U, Koch N, Zhang X, Mohan R: Monte carlo simulations for configuring and testing an analytical proton dose-calculation algorithm. Phys Med Biol 2007, 52(15):4569-4584.
• [35]Das IJ, Cheng CW, Watts RJ, Ahnesjo A, Gibbons J, Li XA, Lowenstein J, Mitra RK, Simon WE, Zhu TC: Accelerator beam data commissioning equipment and procedures: Report of the TG-106 of the therapy physics committee of the AAPM. Medical Physics 2008, 35(9):4186-4215.
• [36]Fraass B, Doppke K, Hunt M, Kutcher G, Starkschall G, Stern R, Van Dyke J: American association of physicists in medicine radiation therapy committee task group 53: Quality assurance for clinical radiotherapy treatment planning. Medical Physics 1998, 25(10):1773-1829.
• [37]ICRU: International comission on radiation units and measurements report 78: Prescribing, recording, and reporting proton-beam therapy (ICRU report 78). J ICRU 2007, 7(2):1-210.
• [38]Brodin NP, Rosenschold PMAF, Aznar MC, Kiil-Berthelsen A, Vogelius IR, Nilsson P, Lannering B, Bjork-Eriksson T: Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol 2011, 50(6):806-816.
• [39]Newhauser WD, Giebeler A, Langen KM, Mirkovic D, Mohan R: Can megavoltage computed tomography reduce proton range uncertainties in treatment plans for patients with large metal implants? Phys Med Biol 2008, 53(9):2327-2344.
• [40]Zhang XD, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang XC, Li YP, Newhauser WD, Gillin M, Mohan R: Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys 2007, 67(2):620-629.
• [41]Urie M, Goitein M, Wagner M: Compensating for heterogeneities in proton radiation-therapy. Phys Med Biol 1984, 29(5):553-566.
• [42]Moyers MF, Miller DW: Range, range modulation, and field radius requirements for proton therapy of prostate cancer. Technol Cancer Res Treat 2003, 2(5):445-447.
• [43]Moyers MF, Miller DW, Bush DA, Slater JD: Methodologies and tools for proton beam design for lung tumors. Int J Radiat Oncol Biol Phys 2001, 49(5):1429-1438.
• [44]Vann A, Dasher B, Chestnut S, Wiggers N: Portal design in radiation therapy. Columbia, S.C: R.L. Bryan Co; 2006.
• [45]Yom SS, Frija EK, Mahajan A, Chang E, Klein K, Shiu A, Ohrt J, Woo S: Field-in-field technique with intrafractionally modulated junction shifts for craniospinal irradiation. Int J Radiat Oncol Biol Phys 2007, 69(4):1193-1198.
• [46]Benjamini Y, Hochberg Y: "Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 1995, 57(1):289-300.
• [47]Howell RM, Scarboro SB, Kry SF, Yaldo DZ: Accuracy of out-of-field dose calculations by a commercial treatment planning system. Phys Med Biol 2010, 55(23):6999-7008.
• [48]Newhauser WD, Fontenot JD, Mahajan A, Kornguth D, Stovall M, Zheng YS, Taddei PJ, Mirkovic D, Mohan R, Cox JD, Woo S: The risk of developing a second cancer after receiving craniospinal proton irradiation. Phys Med Biol 2009, 54(8):2277-2291.
• [49]Taddei PJ, Mahajan A, Mirkovic D, Zhang R, Giebeler A, Kornguth D, Harvey M, Woo S, Newhauser WD: Predicted risks of second malignant neoplasm incidence and mortality due to secondary neutrons in a girl and boy receiving proton craniospinal irradiation. Phys Med Biol 2010, 55(23):7067-7080.